Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Olivia M Cunningham, Sanjana Ravikumar, Craig Snow, Sara M Tolaney, Sarah Sammons, Ann H Partridge, Nancy U Lin
{"title":"在EMBRACE研究中，转移性乳腺癌诊断的年轻年龄与总生存率之间的关系。","authors":"Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Olivia M Cunningham, Sanjana Ravikumar, Craig Snow, Sara M Tolaney, Sarah Sammons, Ann H Partridge, Nancy U Lin","doi":"10.1038/s41523-025-00822-y","DOIUrl":null,"url":null,"abstract":"<p><p>The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"96"},"PeriodicalIF":7.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397373/pdf/","citationCount":"0","resultStr":"{\"title\":\"The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.\",\"authors\":\"Kristen D Brantley, Gregory J Kirkner, Melissa E Hughes, Leticia Varella, Georgia Suggs, Olivia M Cunningham, Sanjana Ravikumar, Craig Snow, Sara M Tolaney, Sarah Sammons, Ann H Partridge, Nancy U Lin\",\"doi\":\"10.1038/s41523-025-00822-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.</p>\",\"PeriodicalId\":19247,\"journal\":{\"name\":\"NPJ Breast Cancer\",\"volume\":\"11 1\",\"pages\":\"96\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397373/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Breast Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41523-025-00822-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00822-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.
The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.
期刊介绍：
npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
